Table 4. Characteristics of the 612 tumours from the patients not treated with preoperative interstitial laser thermo therapy (n=11 and 1 uncertain) or neoadjuvant therapy (n=28) in this study.
| n (%) | Any CYP2C8*4 allele (%) | |
|---|---|---|
| Invasive tumour size | ||
| pis | 14 (2.3) | 28.6 |
| pT1 | 432 (70.6) | 12.0 |
| PT2 | 152 (24.8) | 13.8 |
| pT3 | 12 (12.0) | 8.3 |
| pT4 | 1 (0.2) | 0 |
| Missing | 3 (0.5) | |
| Axillary lymph node involvement | ||
| pN− | 389 (63.8) | 15.9 |
| pN+ | 220 (35.9) | 7.3 |
| Missing | 3 (0.5) | |
| Histological grade | ||
| Grade 1 | 156 (25.5) | 9.3 |
| Grade 2 | 312 (51.0) | 12.2 |
| Grade 3 | 142 (23.2) | 16.9 |
| Missing | 3 (0.5) | |
| Hormone receptor status | ||
| ER+/PR+ | 411 (67.2) | 10.2 |
| ER+/PR− | 111 (18.1) | 16.2 |
| ER−/PR− | 72 (11.8) | 19.4 |
| ER−/PR+ | 4 (0.7) | 0 |
| Missing | 13 (2.1) | |
Abbreviations: CYP=cytochrome P450; ER=oestrogen receptor; PR=progesterone receptor.
The CYP2C8*4 allele was the only genotype that was associated with tumour characteristics. The percentage of patients with at least one CYP2C8*4 allele is indicated in relation to the tumour characteristics.
*Large and inflammatory tumours were treated by neoadjuvant therapy; therefore there is no information presented on these tumours.